Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aureon Laboratories has introduced new Prostate Px+, the first commercial test said to predict prostate cancer progression and disease recurrence at the time of diagnosis.
Subscribe to our email newsletter
Prostate Px+ is based on the results of a large study utilizing data and samples from a cohort of 1,027 men assembled from the Mayo Clinic, Uppsala University, University of Connecticut and Duke University Medical Center. In validation, Aureon’s predictive model identified twice as many high-risk events in low and intermediate risk patients than the best available method.
Ricardo Mesa-Tejada, vice president of pathology and medical director of Aureon Laboratories, said: “Prostate Px+ is the first prognostic test to provide this critical information at diagnosis. This technology represents a new integrated approach known as systems pathology that combines molecular biomarkers, histological and clinical information with advanced mathematics.”